Ipsen and Clementia Pharmaceuticals have entered into an agreement for Ipsen to acquire Clementia for $1.31 billion. The purchase includes Clementia’s key late-stage clinical asset palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases.   A New Drug Application (NDA) for palovarotene for episodic flare-up treatment of FOP is expected to be submitte...